Pharvaris N.V. Ordinary Shares (PHVS)
Stock · NASDAQ · Health Care
$27.72as of 10/16/2026
Price chart
Active signals
Resistance level
$33.11
Industry
Biotechnology: Pharmaceutical Preparations
PHVS Signal Track Record
How signals performed across all stocks →What PHVS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 40 | +1.3% | 57% | September 15, 2026 |
| Bollinger Band Breakout | 26 | +2.8% | 62% | August 12, 2026 |
| Bollinger Band BreakdownActive now | 19 | -2.1% | 42% | September 23, 2026 |
| 200-Day Moving Average TouchActive now | 10 | -4.8% | 40% | October 5, 2026 |
| Any 20-session window (baseline) | +0.4% | 51% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PHVS
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema du…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 148
- Website
- pharvaris.com/
Fundamentals
- 1-day range
- $27.75$29.54
- Market cap
- $2.40B
- P/E (trailing)
- —
- P/E (forward)
- -9.11
- EPS (trailing)
- $-2.62
- Dividend yield
- —
- Beta
- -2.71
- Avg. volume
- 732.6K
52-week range
$20.65$43.25
Next earnings: November 12, 2026 · EPS estimate $-0.72After Closeconfirmed
Forecasts
14 analyst ratings
Buy 91%
Hold 10%
Sell 0%
1-year price forecast
High
$79.27
+186.0%
Median
$60.01
+116.5%
Low
$41.14
+48.4%
Pharvaris N.V. Ordinary Shares Competitors
Chosen by industry and closest market cap.
- PHVSPharvaris N.V. Ordinary Shares$27.74▼ 6.41%Market cap $2.40BP/E —$20.65$43.25
- KLRAKailera Therapeutics Inc. Common Stock$11.25▼ 3.93%Market cap $2.44BP/E —$9.76$28.23
- ZLABZai Lab Limited American Depositary Shares$23.19▼ 1.36%Market cap $2.35BP/E —$12.31$26.6
- PGENPrecigen Inc. Common Stock$6.39▼ 11.25%Market cap $2.47BP/E —$3.04$8.98
- VRDNViridian Therapeutics Inc. Common Stock$19.03▼ 2.71%Market cap $2.32BP/E —$13.18$34.29
- NKTRNektar Therapeutics Common Stock$35.78▼ 5.14%Market cap $2.48BP/E —$33.4$109
- VERAVera Therapeutics Inc. Class A Common Stock$27.88▼ 2.42%Market cap $2.30BP/E —$23.05$56.05
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PHVS Pharvaris N.V. Ordinary Shares | $2.40B | — | $27.74 | ▼ 6.41% | $20.65$43.25 |
| KLRA Kailera Therapeutics Inc. Common Stock | $2.44B | — | $11.25 | ▼ 3.93% | $9.76$28.23 |
| ZLAB Zai Lab Limited American Depositary Shares | $2.35B | — | $23.19 | ▼ 1.36% | $12.31$26.6 |
| PGEN Precigen Inc. Common Stock | $2.47B | — | $6.39 | ▼ 11.25% | $3.04$8.98 |
| VRDN Viridian Therapeutics Inc. Common Stock | $2.32B | — | $19.03 | ▼ 2.71% | $13.18$34.29 |
| NKTR Nektar Therapeutics Common Stock | $2.48B | — | $35.78 | ▼ 5.14% | $33.4$109 |
| VERA Vera Therapeutics Inc. Class A Common Stock | $2.30B | — | $27.88 | ▼ 2.42% | $23.05$56.05 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Reported Earlier, Pharvaris Says Lancet-Published Phase 3 Data Show Deucrictibant IR Delivered Symptom Relief In 1.28 Hours And Complete Resolution In 11.95 Hours For HAE Attacks, With NDA And MAA Under Reviewbenzinga · 10/9/2026
- Reported Earlier, Pharvaris Says Lancet-Published Phase 3 Data Show Deucrictibant IR Delivered Symptom Relief In 1.28 Hours And Complete Resolution In 11.95 Hours For HAE Attacks, With NDA And MAA Under ReviewBenzinga · 10/9/2026
- Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The LancetYahoo · 10/8/2026
- Could Real-World HAE Oral Preference Data Be a Pivotal Signal for Pharvaris' (PHVS) Strategy?Yahoo · 10/8/2026
- Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in TherapyYahoo · 10/5/2026
- What Does Pharvaris (PHVS) Phase 3 HAE Success Mean Now?Yahoo · 9/19/2026
- BioCryst Eyes $1B Rare-Disease Future Through External InnovationYahoo · 9/19/2026
- Pharvaris N.V. (PHVS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/15/2026
- PHVS Stock Rises 10% in a Month: What Is Driving the Rally?Yahoo · 9/15/2026
Insider Activity
Insider Actions →Acquired
172.6K
Disposed
453.8K
- Viviane Monges · September 23, 2026 · Option Exercise12.0K @ $8.05
- Viviane Monges · September 23, 2026 · Sale12.0K @ $33.05
- Peng Lu · September 22, 2026 · Option Exercise45.3K @ $2.59
- Johannes Gerardus Christiaan Petrus Schikan · September 22, 2026 · Option Exercise800 @ $20
- Johannes Gerardus Christiaan Petrus Schikan · September 22, 2026 · Sale800 @ $36.19
- David W. Nassif · September 21, 2026 · Gift500
- David W. Nassif · September 21, 2026 · Sale6.0K @ $36.47
- Peng Lu · September 17, 2026 · Option Exercise86.7K
- Peng Lu · September 17, 2026 · Option Exercise13.3K
- Peng Lu · September 17, 2026 · Sale100.0K @ $35
- Peng Lu · September 17, 2026 · Option Exercise100.0K @ $2.59
- Johannes Gerardus Christiaan Petrus Schikan · September 17, 2026 · Sale200.0K @ $35
- Robert Glassman · September 17, 2026 · Option Exercise14.5K @ $18.14
- Robert Glassman · September 17, 2026 · Sale14.5K @ $38.56
- Anne Lesage · September 17, 2026 · Sale20.0K @ $38.27
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Pharvaris publishes Phase 3 deucrictibant data in The Lancet
Pharvaris reported Phase 3 results for deucrictibant IR in The Lancet, showing symptom relief in 1.28 hours and complete resolution in 11.95 hours for HAE attacks. The company stated that the New Drug Application and Marketing Authorization Application are currently under review. Additional real-world data on patient preferences was also published, providing context for the treatment strategy.
Pharvaris publishes Phase 3 deucrictibant data in The Lancet. Pharvaris reported Phase 3 results for deucrictibant IR in The Lancet, showing symptom relief in 1.28 hours and complete resolution in 11.95 hours for HAE attacks. The company stated that the New Drug Application and Marketing Authorization Application are currently under review. Additional real-world data on patient preferences was also published, providing context for the treatment strategy.